China will continue to ramp up volume-based procurement (VBP) policies that bring down drug and device prices for public hospitals with volume. Governmental agencies at the local and national levels ...

China’s volume-based procurement (VBP) policy has impacted several medical device companies this year, including Medtronic. In fact, Medtronic CFO Karen Parkhill mentioned in February, during the ...

Not only has China banned the import and sale of GSK’s Avodart (dutasteride) soft capsules through its national bulk-buy drug procurement program. It has barred the company's participation in the ...

Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but ...

The European Commission (EC) will restrict Chinese companies from EU government purchases of medical devices exceeding €5m ($5.7m). The move comes after a report found that 87% of public procurement ...